The World Health Organization has declared the ongoing COVID-19 outbreak, caused by the virus SARS-CoV-2, a global pandemic. The IPD is focused on seven research projects that we hope will have an immediate impact:
Antiviral and anti-inflammatory proteins
Hyperstable binding proteins are being designed to target the SARS-CoV-2 spike glycoprotein, the human ACE-2 receptor, and receptors implicated in cytokine storms.
A new generation of protease inhibitors made from structured macrocycles with non-canonical residues are being designed to stop SARS-CoV-2 proteases.
Screening existing drugs
Over 8,000 FDA-approved compounds are being screened in silico for binding to structures from the SARS-CoV-2 proteome.
Modeling the viral proteome
Rosetta is being used to model the 3D structures of important proteins from the SARS-CoV-2 coronavirus.
Using technology created at the IPD, an array of candidate COVID-19 vaccines has been designed, characterized, and fast-tracked into animal testing.
LOCKR technology is being reconfigured into a sensitive in-solution serological assay to rapidly detect SARS-CoV-2 antibodies in body fluid samples.
Nanoparticles to treat inflammation
New methods for controlling cell signaling are being applied to create new nanoparticle super-agonists for regenerative medicine.
We are empowering everyone to join the fight against COVID-19 through Foldit and Rosetta@Home. Foldit player’s solutions to our new coronavirus puzzles are being manufactured and tested in the lab.